TRANBERG Thermal Therapy System developer Clinical Laserthermia Systems AB (publ) (STO:CLS-B) announced on Thursday that it has received additional orders from ClearPoint Neuro, Inc (Nasdaq:CLPT), a medical device company, valued at approximately SEK7.5m.
These orders are for ClearPoint Prism products as part of ClearPoint Neuro's North American market launch initiated in early June this year. This follows previous orders totaling approximately SEK10.5m received around the turn of the year 2023/2024.
CLS and ClearPoint Neuro aim to develop and commercialize a next-generation, fully integrated laser therapy system for high-precision MRI-guided stereotactic laser ablation in neurosurgery. The integrated product solution offers streamlined workflows for identifying, navigating and positioning sterile laser applicators in target tissues, with MRI-guided monitoring and control of temperature and ablation progress.
Recent strategic steps include obtaining US-FDA 510(k) clearance for ClearPoint Neuro's Prism Bone Anchor Accessory, further strengthening the product offering and expanding the market in the US.
(EUR1=SEK11.19)
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma